Page 144 - NPPA full book

Thrust of Indian Pharma on R&D and

Innovation

Valued at US$ 50 billion, Indian pharmaceutical industry has come a

long way since independence in 1947 when the country was heavily

dependent on imports and aids for medicines and other basic needs.

Today we are the third largest pharmaceutical industry in the world

and now eye the next wave of growth and excellence. Leveraging

innovation capabilities is a pre-requisite to transform India into
Mr. Pankaj R. Patel
a powerhouse in the life-sciences sector. The future will be about Chairman, Zydus Group

bringing in greater patient-centricity and customized solutions

which will impact the quality of life in different ways. India will be exploring new approaches through biopharmaceuticals,

looking at new healthcare delivery models and continuing with national missions and dedicated programmes like ‘Make

in India’ and ‘Aatmanirbhar Bharat’ (Self Reliant India).

India’s Research Scientist are highly capable of delivering noble drugs that addressed unmate healthcare needs. Lipaglyn,

the first drug anywhere in the world for Diabetic Dyslipidemia, Bylipsa, another first-in-the world treatment for NAFLD

and NASH, Oxemia, a first-in-India therapy for Chronic Kidney Disease Patients and capabilities to develop and supply

vaccines to the world including the first-in-the-world plasmid DNA technology, are all products of Indian Innovation.

A strong foundation exists today; we just need to catapult ourselves into the future. The growth of the innovation

ecosystem will decide the trajectory of the Indian pharma sector. A robust regulatory landscape, investments in R&D,

setting-up of innovation hubs, academia and industry linkages and a favourable policy landscape will add on to India’s

cost-efficient manufacturing prowess for affordable medicines.

134